GAPVAC-101: First-in-human trial of a highly personalized peptide vaccination approach for patients with newly diagnosed glioblastoma.

• Wick, Wolfgang Neurology Clinic, DKFZ, DKTK, Heidelberg, Germany;
• Dietrich, Pierre-Yves Hopitaux Universitaires De Geneve, Geneve 14, Switzerland;
• Kuttruff, Sabrina Immatics Biotechnologies GmbH, Tuebingen, Germany;
• Hilf, Norbert immatics biotechnologies GmbH, Tübingen, Germany;
• Frenzel, Katrin Biopharmaceutical New Technologies (BioNTech) Corporation, Mainz, DE;
• Admon, Arie Technion, Haifa, Israel;
• van der Burg, Sjoerd H. Leiden University Medical Center, Leiden, Netherlands;
• von Deimling, Andreas Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University Heidelberg, Heidelberg, Germany;
• Gouttefangeas, Cecile Institute of Cell Biology, Dept. of Immunology, University of Tuebingen, Tuebingen, Germany;
• Kroep, Judith R. Leiden University Medical Center, Leiden, Netherlands;
• Martinez-Ricarte, Francisco Vall d’Hebron University Hospital, Barcelona, Spain;
• Okada, Hideho University of Pittsburgh Cancer Institute, Pittsburgh, PA;
• Ottensmeier, Christian H.H Cancer Research UK, Southampton, United Kingdom;
• Ponsati, Berta BCN Peptides, Barcelona, Spain;
• Poulsen, Hans Skovgaard Rigshospitalet, København Ø, DK;
• Stevanovic, Stefan Institute of Cell Biology, Dept. of Immunology, University of Tuebingen, Tuebingen, Germany;
• Tabatabai, Ghazaleh Department of Neurology, University Hospital, Zürich, Switzerland;
• Rammensee, Hans-Georg Institute of Cell Biology, Dept. of Immunology, University of Tuebingen, Tuebingen, Germany;
• Sahin, Ugur TRON GGmbHl, Mainz, Germany;
• Singh, Harpreet Immatics US, Inc., Houston, TX;

Cancer Research

Oncology